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The TAR DNA binding protein-43 (TDP-43) has been identified as a major constituent of inclusions found in 
frontotemporal dementia with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS).  To 
determine a possible role for TDP-43 in Alzheimer’s disease (AD), a site-directed caspase-cleavage antibody to 
TDP-43 based upon a known caspase-3 cleavage consensus site within TDP-43 at position D219 was designed.  In 
vitro, this antibody labeled the predicted 25 kDa caspase-cleavage fragment of TDP-43 without labeling full-length 
TDP-43 following digestion of recombinant TDP-43 with caspase-3 or treatment of Hela cells with staurosporine. 
Application of this antibody in postmortem brain sections indicated the presence of caspase-cleaved TDP-43 in 
Hirano bodies, tangles, reactive astrocytes and neuritic plaques of the AD brain.  Caspase-cleaved TDP-43 also co-
localized with ubiquitin labeled neurons as well as dystrophic neurites within plaque regions.  These results suggest 
that caspase-cleaved TDP-43 is a major pathological finding in AD and may contribute to the neurodegeneration 




The TAR DNA binding protein-43 (TDP-43) has been identified as a major disease protein in frontotemporal lobar 
degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS), {Neumann, 
2006 #2634}. TDP-43 is a nuclear protein that is highly conserved and ubiquitously expressed in all tissues 
examined and whose function may be exon skipping and splicing inhibitory activity {Buratti, 2004 #2686}.  Other 
functions for TDP-43 include the biogenesis of mRNA and providing scaffolding for nuclear bodies {Kwong, 2008 
#2685} 
 
In FTLD-U and ALS, TDP-43 immunoreactivity has been demonstrated within ubiquitin-positive neuronal 
cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions, and neuronal dystrophic neurites {Kwong, 2007 
#2639}.  In addition, recent studies have suggested that TDP-43 may also be a substrate for caspase-3 cleavage 
{Zhang, 2007 #2635}, generating an approximate 25 kDa fragment that has been identified in brain fractions from 
FTLD-U and ALS subjects {Neumann, 2006 #2634; Zhang, 2007 #2635; Amador-Ortiz, 2007 #2637}.  The 
presence of TDP-43 immunoreactivity has also been investigated in Alzheimer’s disease (AD) with one study 
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indicating a complete lack of TDP-43 labeling {Josephs, 2008 #2641}, while other studies demonstrated TDP-43 
within NCIs and a subset of neurofibrillary tangles (NFTs) in a minority of AD cases examined {Amador-Ortiz, 
2007 #2637; Higashi, 2007 #2642; Uryu, 2008 #2688}.  Based upon these results, TDP-43 does not appear to be a 
major pathological feature associated with AD.   
 
In AD, numerous studies have now demonstrated the activation of caspases and cleavage of cellular proteins 
including the amyloid precursor protein, fodrin, actin, GFAP and tau {Gervais, 1999 #717; Rohn, 2001 #1798; 
Rohn, 2001 #1799; Yang, 1998 #2411; Mouser, 2006 #2532; Rissman, 2004 #2563; Cotman, 2005 #2544}.  
Therefore, we hypothesized that the lack of immunoreactivity to full-length TDP-43 antibodies in AD may reflect 
the fact that TDP-43 is cleaved by caspases and the epitopes to which full-length TDP-43 antibodies recognized is 
loss, thus explaining the apparent lack of labeling in the majority of AD cases examined.  To test this hypothesis and 
to determine whether caspase-cleaved TDP-43 is present in the AD brain, we designed a site-directed caspase 
cleavage antibody to TDP-43 based upon a known caspase cleavage consensus site within TDP-43 at position 219 
(DVMD) {Zhang, 2007 #2635}. Application of this antibody in postmortem brain sections revealed widespread 
immunoreactivity in Hirano bodies, tangles, reactive astrocytes and within plaque-rich regions of all AD cases 
examined.  Collectively, these results provide further support for the role of caspases in promoting the pathology 
associated with AD.  Moreover, due to the extent and frequency of TDP-43 pathology uncovered, it is proposed that 




Examination of the TDP-43 protein sequence indicates a putative caspase-cleavage consensus site, DVMD219, that 
would generate an amino-terminal fragment of approximately 25 kDa following cleavage by caspases. We 
synthesized rabbit, polyclonal antibodies to this amino-terminal fragment within TDP-43 and tested their validity as 
specific probes for TDP-43 CCPs in a cell-free system or in a model system of apoptosis.  Cell-free digestion of 
recombinant human TDP-43 with caspase-3 was undertaken and extracts were probed with the TDP-43 CCP (herein 
referred to as TDPccp) antibody (Fig. 1A).  In this case, although no reactivity to full-length TDP-43 was observed 
under control conditions, TDPccp detected the predicted caspase-cleavage fragment (25 kDa) as well as several high 
molecular weight species of TDP-43 following incubation with caspase-3 (Fig. 1A, lane labeled “Digest Casp-3”). 
To extend these findings, an in vitro model of apoptosis was employed consisting of HeLa cells.  HeLa cells were 
incubated in the presence of the apoptotic insult, SST, for 24 hrs and cell extracts were analyzed by Western blot 
utilizing the TDPccp antibody.  A single doublet band at 25 kDa corresponding to the predicted molecular weight 
following cleavage of TDP-43 at DVMD219 was apparent following treatment with SST (Fig. 1B).  The appearance 
of this SST-induced cleavage fragment was prevented following pretreatment of HeLa cells with the broad caspase 
inhibitor, Z-VAD (Fig. 1B, lane marked “SST + Z-VAD).  A previous study has also identified a doublet band 
running at 25 kDa fragment of TDP-43 following treatment of extracts with phosphatase {Amador-Ortiz, 2007 
#2637}.  This suggests that in addition to proteolytical processing, TDP-43 may also undergo abnormal 
phosphorylation. It is noteworthy the TDPccp antibody did not react with full-length TDP-43 (Fig. 1B).  The 
presence of full-length TDP-43 in HeLa cells was confirmed following Western blot analysis employing a 
commercial polyclonal antibody to TDP-43 (Fig. 1C).  Interesting, this full-length antibody to TDP-43 was unable to 
detect the 25 kDa caspase-cleavage fragment following treatment of HeLa cells with SST (Fig. 1C).  
 
 
Following verification that TDPccp is a specific probe for caspase-cleaved TDP-43, immunohistochemical analysis 
was performed on post-mortem hippocampal brain sections from AD subjects and age-matched controls. Bright-
field immunohistochemical analysis employing the TDPccp antibody revealed infrequent labeling in age-match 
control subjects (Fig. 2A).  In general, diffuse staining in control cases was neuronal and was predominantly 
confined within the hippocampus proper.  In contrast, intense, widespread labeling of the TDPccp antibody was 
observed in all AD cases examined.  Strong immunolabeling was identified within Hirano bodies (Fig. 2B, 
arrowheads) and these structures were found exclusively within the hippocampus proper (Fig. 2C).  Hirano bodies 
are rod-shaped, cytoplasmic inclusions that are found predominantly within the hippocampus in a variety of 
neurodegenerative diseases, including AD {Hirano, 1994 #2677}.  Labeling of Hirano bodies was also a major 
finding in two cases neuropathologically diagnosed as being AD/PD (data not shown). It is noteworthy that a 
previous study identified caspase-cleaved actin within Hirano bodies of AD subjects and revealed a similar staining 
pattern to what was observed with the TDPccp antibody in the present study {Rossiter, 2000 #2676}. 
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Another prominent feature found in AD cases was the extensive labeling of TDPccp within plaque-rich regions (Fig. 
2D and E).  Labeled plaques were found throughout the hippocampus and were also identified in the entorhinal 
cortex.  TDPccp immunoreactivity was also identified within reactive astrocytes (Fig. 2B, arrows) and within 
neurons with apparent tangle morphology (Fig. 2F, arrows). 
 
Specificity of the TDPccp antibody as a specific probe for caspase-cleaved TDP-43 in AD was confirmed following 
experiments with preimmune serum and preadsorbed antibody (Fig. 3).  In this manner, there was a complete lack of 
specific staining in serial AD sections in which preimmune sera was utilized, although nonspecific staining of blood 
vessels was evident (Fig. 3C).  Staining with TDPccp was prevented under conditions whereby purified TDPccp was 
preadsorbed with the peptide used as the immunogen (Fig. 3F). 
 
Double-label immunofluorescence experiments were undertaken to examine a possible relationship between 
caspase-cleaved TDP-43 and caspase-cleaved tau.  To identify caspase-cleaved tau within tangles, a monoclonal 
antibody (TauC3) developed by Gamblin et al. was employed, which is specific for the C-terminal caspase-cleavage 
of tau at aspartic acid 421 {Gamblin, 2003 #694}.  Co-localization of both antibodies within neurons was evident in 
the hippocampus of all AD cases examined (Fig. 4A-C).  In addition, we were able to demonstrate the co-
localization of TauC3 and TDPccp within dystrophic neurites in plaque regions of the hippocampus (Fig. 4C and D).  
The concurrence of these two antibodies within neurons and neuritic plaques confirms the specificity of the TDPccp 
antibody as a marker for caspase-cleaved TDP-43.  Finally, co-localization experiments with an anti-Aβ antibody 
and an antibody to GFAP confirmed the presence of TDPccp within plaque-rich regions as well as within reactive 
astrocytes of the AD brain (Fig. 4E and F).  Previous studies have demonstrated the activation of caspases within 
reactive astrocytes and the occurrence of caspase-cleaved glial fibrillary acidic protein in the AD brain {Mouser, 
2006 #2532}. 
 
Because previous studies have shown that pathologic TDP-43 is not only cleaved to generate C-terminal fragments, 
but is also ubiquinated in affected brain and spinal cord of FTLD-U and ALS {Kwong, 2007 #2639}, double 
immunohistochemical experiments were performed with the TDPccp antibody and a monoclonal antibody to 
ubiquitin.  Evidence for co-localization of these two markers was apparent within dystrophic neurites (Fig. 5A and 
C), as well as within neurons with apparent tangle morphology (Fig. 5B and D).  The presence of caspase-cleaved 
TDP-43 together with ubiquinated-positive structures suggests that as in FTLD-U and ALS, pathological TDP-43 
undergoes similar turnover events in the AD brain.   
 
In support of our findings, previous studies have shown the occurrence of pathological TDP-43 in a minority of AD 
cases examined {Amador-Ortiz, 2007 #2637; Higashi, 2007 #2642}.  For both studies, the same commercial 
antibody to full-length TDP-43 was used (polyclonal, rabbit, ProteinTech, USA).  Thus, immunohistochemical 
analysis was carried out using this antibody and a similar monoclonal antibody to TDP-43 from the same company.  
Figure 6 depicts the results of experiments utilizing these two antibodies to full-length TDP-43.  In general, we 
found widespread neuronal labeling throughout the hippocampus following application of either of these two 
antibodies.  The staining appeared to be primarily nuclear, and we were unable to identify any pathological 
structures labeled with the monoclonal antibody to TDP-43 in the majority of cases examined.  In addition to nuclear 
labeling of TDP-43, the polyclonal antibody to TDP-43 immunolabeled dystrophic neurites as well as structures 
within plaque regions in one AD case out of five, which corresponds to the frequency of pathological TDP-43 found 




In the present study, caspase-cleaved TDP-43 has been identified as a major pathological finding in the 
hippocampus of the AD brain.  The identification of caspase-cleaved TDP-43 in AD was accomplished using a 
caspase-cleavage site-directed antibody to TDP-43 based upon a known caspase-cleavage site at position 219.  
Cleavage at this site by caspase-3 would generate a predicted 25 kDa fragment of TDP-43, which has been identified 
as a major molecular weight species in brain extracts of ALS and FTLD-U {Amador-Ortiz, 2007 #2637; Neumann, 
2006 #2634; Zhang, 2007 #2635}.  Validation of this antibody, termed the TDP caspase-cleavage product (CCP) 
antibody consisted of several observations: 1) TDPccp immunolabeled a band at 25 kDa following cell-free caspase-
3 digestion of TDP-43 or following treatment of HeLa cells with the apoptotic insult, SST.  The presence of this 25 
kDa band in SST-treated cells was completely prevented following pretreatment with the caspase inhibitor, Z-VAD; 
2) TDPccp did not react with full-length TDP-43, whereas under similar experimental conditions an antibody to full-
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length TDP-43 did; 3) TDPccp labeled neurons displayed a cytoplasmic distribution that is characteristic of 
pathological TDP-43 {Kwong, 2007 #2639}; 4) Staining of TDPccp in the AD sections was completely prevented 
following preadsorption of the affinity-purified antibody with free peptide or utilizing preimmune serum; 5) a 
protein-protein BLAST alignment of the seven amino acid residues chosen as the immunogen, QYGDVMD, lists 
TDP-43 as the only predicted human protein.  Taken together, these data support the notion that TDPccp is a 
specific marker for caspase-cleaved TDP-43. 
 
Application of TDPccp in AD postmortem hippocampal brain sections revealed labeling of Hirano bodies, neuritic 
plaques, neurons with apparent tangle morphology and reactive astrocytes. Due to the extent and frequency of 
pathology uncovered following application of this caspase-cleaved TDP-43 antibody, it is proposed that cleaved 
TDP-43 may represent a major disease component in AD.  These results provide further support for a role of 
apoptosis in general, and caspases in particular in the disease progression associated with AD.  Numerous studies 
have documented caspase activation and cleavage of proteins in the AD brain {LeBlanc, 2005 #2581}.  Caspase-
cleaved TDP-43 can be added to the already extensive list of proteins demonstrated to be substrates for caspases in 
Alzheimer’s including APP {Gervais, 1999 #717}, actin {Yang, 1998 #2411}, fodrin {Rohn, 2001 #1799} and tau 
{Rissman, 2004 #2563; Gamblin, 2003 #694}.  Recent evidence suggests that caspases may play an early proximal 
role in promoting the pathology underlying AD including the formation of NFTs and processing of APP and tau 
{Spires-Jones, 2008 #2666; Rohn, 2008 #2644}.  However, an important caveat to these studies has been the lack of 
evidence for apoptosis in the AD brain and the role for apoptosis in the AD remains a controversial hypothesis 
{Jellinger, 2006 #2687}.  One possibility is the activation of caspases and the full completion of the apoptotic 
program and eventual cell death may be largely separated in time {Rohn, 2002 #1808}. 
 
Previous studies have demonstrated the presence of pathological TDP-43 in the AD brain {Amador-Ortiz, 2007 
#2637; Higashi, 2007 #2642}. In one study, the authors found TDP-43-positive inclusions in roughly 33% of the 
AD cases examined with TDP-43 immunoreactivity being found principally within NCIs but also within dystrophic 
neurites {Higashi, 2007 #2642}. In another exhaustive study by Amador-Ortiz et al., the authors examined 167 cases 
of AD and found pathological TDP-43 in the form of dystrophic neurites and within occasional NFTs in 
approximately 20% of the cases examined {Amador-Ortiz, 2007 #2637}.  Of interest was the fact that in both 
studies the same commercial antibody to full-length TDP-43 was utilized (a rabbit polyclonal antibody from 
Proteintech Group, Inc, USA).  Based on previous studies, it appears this antibody reacts with the C-terminal region 
of TDP-43 {Neumann, 2006 #2634}.  The ability of this full-length TDP-43 polyclonal antibody to detect the 25 
kDa caspase-cleaved fragment in an in vitro model system of apoptosis was tested.  Although the antibody readily 
recognized full-length TDP-43 under these conditions, it did not immunolabel the 25 kDa caspase-cleaved fragment 
of TDP-43 (Fig. 1B). Further, immunohistochemical analysis utilizing this commercial TDP-43 antibody indicated 
labeling within plaques, apparent NFTs and dystrophic neurites in a minority of AD cases examined.  However, 
unlike TDPccp, this commercial polyclonal antibody to TDP-43 did not label Hirano bodies in the AD brain. These 
data suggest the difference observed in the staining between these two antibodies may reflect the fact the TDPccp in 
contrast to the full-length polyclonal TDP-43 was designed to recognize the N-terminal upstream fragment of TDP-
43, which may be more stable or resistant to turnover than the C-terminal fragment.  Thus, in AD following caspase 
cleavage, the N-terminal fragment of TDP-43 may persist and accumulate allowing for a more consistent detection 
following immunohistochemical analysis with the TDPccp antibody. 
 
The ability of caspases to cleave TDP-43 may convert TDP-43 to a pathological form allowing for its redistribution 
to the cytoplasm as well as abnormal accumulation.  Biochemical studies of TDP-43 have indicated the presence of 
ubiquinated high-molecular weight species and C-terminal fragments of TDP-43 in FTLD-U, ALS and the AD brain 
{Neumann, 2006 #2634; Amador-Ortiz, 2007 #2637}.  It is interesting to speculate whether proteolytic cleavage of 
TDP-43 enhances its ability to self-aggregate as has been shown for other proteins such as alpha-synuclein {Dufty, 
2007 #2643}.  Whether the caspase-cleavage of TDP-43 facilitates the formation of aggregated species and to what 
extent these species are neurotoxic will require further investigation. 
 
In conclusion, caspase-cleaved TDP-43 has been identified as a major pathological finding in the AD brain.  The 
presence of caspase-cleaved TDP-43 adds to the long list of substrates demonstrated to be targets for proteolytic 
cleavage by this family of enzymes in the AD brain.  Future studies are needed to determine whether caspase 
cleavage of TDP-43 is an early or late event, is positively associated with other pathological features of AD, and 
whether pathological forms of TDP-43 contribute to the neurodegeneration associated with this disease. 
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4. Experimental Procedure 
 
Materials. The mouse anti-GFAP antibody (MAB3402), mouse TauC3 antibody (caspase-cleaved tau antibody), 
anti-Aβ mAb 1560 (clone 6E10), and ubiquitin (MAB1510: monoclonal, mouse) was purchased from Chemicon 
International (Temecula, CA). Two antibodies to full-length (FL) TDP-43 were purchased from Proteintech Group,  
 
Inc.: polyclonal rabbit TARDBP (10782-2-AP) and a mouse monoclonal TARDBP antibody (60019-2-Ig).  The 
beta-actin rabbit polyclonal antibody was from AbCam (Cambridge, MA). Z-Val-Ala-Ala-Asp (OMe)-FMK (Z-
VAD) was from Enzyme Systems Products (Livermore, CA). Staurosporine (SST) was purchased from Calbiochem 
(La Jolla, CA). 
 
Generation of the polyclonal caspase-cleaved TDP-43 antibody.  Polyclonal antibodies were synthesized based 
upon a putative caspase cleavage consensus site (DVMD219) within TDP-43. We chose the peptide CQYGDVMD, 
which represents the amino-terminal upstream neoepitope fragment of TDP-43 that would be generated following 
cleavage by caspases.  Following synthesis, this peptide was coupled to KLH and injected into rabbits. The resulting 
sera (verified by ELISAs) were used to affinity purify antibodies using a sulfolink column coupled with the peptide 
CQYGDVMD. For this antibody, synthesis of peptides, injections of immunogens, and collection of antisera were 
contracted out to Bethyl laboratories (Montgomery, TX). 
 
Cell Culture 
Human HeLa cells (ATCC, Manassas, VA) were grown in Eagle’s Minimal Essential medium (ATCC, #30-2003) 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin.  To initiate apoptosis, 
cells were treated for 24 hr with the apoptotic insult staurosporine (SST) in serum-free media. SST was made up as a 
5 mM stock in sterile DMSO and diluted 1:100 in BSA/PBS before addition to cell cultures.  Experiments were also 
carried out in the presence of the pan caspase inhibitor Z-VAD.  Z-VAD was prepared as a 50 mM stock in sterile 
DMSO.  To permit adequate cellular loading, Z-VAD was added 1 hour before insult. 
 
Cell-free digestion of TDP-43 
To examine whether caspase-3 can cleave TDP-43, 20 µg of purified human recombinant TDP-43 was incubated 
with active human recombinant caspase-3 in 2x reaction buffer containing 10 mM DTT for two hours at 37°C.  
Reactions were terminated by the addition of 5x sample buffer and stored at -20°C until analyzed. 
 
Western blot analysis 
HeLa cell extracts were processed for Western blot analysis. Proteins were separated by 12% SDS-PAGE and 
transferred to nitrocellulose.  Transferred slabs were stained in coomassie blue to verify equal loading between 
samples.  Membranes were incubated in the TDP-43 caspase-cleavage product antibody (TDPccp, 1:500) or rabbit 
polyclonal FL TDP-43 (Proteintech, 1:500) and primary antibodies were visualized using goat anti-rabbit HRP-
linked secondary (1:5,000; Jackson’s Laboratory, West Grove, PA), followed by ECL detection.  All samples were 
analyzed for protein content using the BCA assay (Pierce) to ensure equal protein loading. 
 
Human Subjects 
Autopsy brain tissue from the hippocampus and entorhinal cortex of seven neuropathologically confirmed AD cases 
and five nondemented cases diagnosed as normal was studied.  In addition, two cases neuropathologically 
designated as AD/Parkinson’s (PD) were also studied.  Human brain tissues used in this study were provided by the 
Institute for Brain Aging and Dementia Tissue Repositories at the University of California, Irvine. 
 
Immunohistochemistry and Immunofluorescence Microscopy 
Free-floating 40 µm-thick serial sections were used for immunohistochemical and immunofluorescence studies as 
previously described {Rohn, 2002 #1807}.  Antibody dilutions were the following: TDPccp (1:100), GFAP (1:400), 
anti beta-amyloid mAb 1560 clone 6E10 (1:400), FL TDP-43 (mouse and polyclonal, 1:100) and mAb TauC3 
(1:100).  To visualize beta-amyloid staining, sections were pretreated for 7 minutes in 95% formic acid.  Antigen 
visualization was determined using ABC complex (ABC Elite immunoperoxidase kit, Vector labs), followed by 
DAB substrate (Vector Labs). For immunofluorescence co-localization studies, antigen visualization was 
accomplished using an Alexa fluor 488-labeled tyramide (green, Ex/Em = 495/519) or streptavidin Alexa Fluor 555 
(red, Ex/Em = 555/565), both from Invitrogen (Carlsbad, CA). 
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Abbreviations: 
AD- Alzheimer’s disease 
Aβ- beta amyloid 
CCPs- caspase-cleavage products 
FTLD-U frontaltemporal lobar degeneration with ubiquitin-positive inclusions 
GFAP- glial fibrillary acidic protein 
NFTs- neurofibrillary tangles 
SST- Staurosporine 
TDP-43- TAR DNA-binding protein-43 
TDPccp-TDP-43 caspase cleavage product antibody 
 
 
Figure 1. Characterization of TDPccp antibody by Western blot analysis.  
(A): Recombinant human TDP-43 was incubated in the presence or absence of caspase-3 for 2 hours at 37°C.  
Samples were separated by SDS-PAGE, transferred to nitrocellulose and probed with affinity-purified TDPccp 
antibody (1:500). Western blot analysis indicated that the TDPccp antibody recognizes a principle 25 kDa fragment 
following digestion with caspase-3. (B): Cell extracts from Hela cells treated with 1 µM staurosporine (SST) were 
run on 12% SDS-PAGE gels for Western analysis and were probed with purified TDPccp.  A prominent doublet 
band at 25 kDa was labeled that was absent after pretreatment of Hela cells with the caspase inhibitor, Z-VAD.  No 
reactivity to full-length TDP-43 was observed (lane marked control, Panel B).  (C): Identical experimental set-up in 
this case samples were probed with a commercially available antibody to TDP-43, which recognizes full-length 
TDP-43.  This antibody recognized full-length TDP-43, but did not immunolabel the 25 kDa caspase-cleaved 
fragment full-length TDP-43, but did not immunolabel the 25 kDa caspase-cleaved fragment (B). 
 
Figure 2. Detection of caspase-cleaved TDP-43 in the hippocampus of the Alzheimer’s disease brain.  
 (A): Representative age-matched control case with affinity-purified TDPccp (1:100) showing weak labeling within 
neurons of the hippocampus.  (B-F): Representative staining with TDPccp in AD cases illustrating widespread 
labeling of the antibody within Hirano bodies (arrowheads, B and C), reactive astrocytes (arrows, B), within plaque-
rich regions (low field, D; high field, E), and NFTs (arrows, F).  All panels are representative staining in the 
hippocampus.  Scale bars are equivalent to 10 µm except panel D, which represents 50 µm. 
 
Figure 3.  Confirmation of specificity of the TDPccp antibody by immunohistochemistry.   
(A-C): Serial sections from a representative AD case were incubated with immunized serum (A and B) or 
preimmune serum (C).  Specific staining was only observed following application of immunized serum.  (D-F): 
Serial AD sections were immunolabeled with purified TDPccp (1:200) and labeling of Hirano bodies (B), dystrophic 
neurites (arrowhead, D), plaques (arrow, D), or reactive astrocytes (E) was observed.  In contrast, staining with 
purified TDPccp was prevented after preadsorption with free peptide (F).  All scale bars represent 10 µm, except for 
Panel F, which represents 20 µm. 
 
Figure 4.  Caspase-cleaved TDP-43 co-localizes with caspase-cleaved tau and is evident within astrocytes as 
well as plaque-rich regions of the Alzheimer’s brain.  (A-D): Overlap immunofluorescence images using a 
monoclonal antibody to caspase-cleaved tau (1:100, green) and TDPccp (1:100, red).  Yellow, orange coloring 
represents areas where markers are overlapping.  Co-localization of the two antibodies was evident within tangle-
bearing neurons (A and B) as well as within dystrophic neurites in plaques (arrows, C and D).  (E):  Overlap 
immunofluorescence image showing caspase-cleaved TDP-43 in green and beta-amyloid in red (mAb 1560, clone 
6E10).  Notice in this case, there is no co-localization of the two  
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antibodies, indicating that although labeling is occurring in the same region, beta-amyloid is extracellular while 
caspase-cleaved TDP-43 is intra-neuronal.  (F): Double immunofluorescence labeling in reactive astrocytes of the 
AD brain utilizing a monoclonal antibody to full-length GFAP (green, 1:400) and TDPccp (red, 1:100).  Co-
localization of the two antibodies was evident within astrocytes of the AD brain.  All scale bars represent 10 µm. 
 
Figure 5.  The TDPccp antibody co-localizes with an anti-ubiquitin mAB antibody in the AD brain. 
Representative double immunostaining with TDPccp (red brown) and ubiquitin (blue gray) in the hippocampus of 
the AD brain.  Note the co-localization of both markers within plaques (arrow, A), neurons with apparent NFT 
morphology (B and D), and Hirano bodies (arrow, C).  Scale bars represent 10 µm. 
 
Figure 6.  Full-length antibodies to TDP-43 reveal widespread nuclear and pathological labeling within the 
hippocampus of the AD brain. Two different antibodies to full-length TDP-43 were examined by 
immunohistochemistry utilizing hippocampal brain sections from representative AD cases. Both a commercially 
available monoclonal antibody to full-length TDP-43 (A and B) or a polyclonal antibody to full-length TDP-43 (C 
and D) was employed. Application of the monoclonal antibody to FL TDP-43 revealed widespread nuclear labeling 
within neurons in all hippocampal regions examined (A and B).  In contrast, the rabbit polyclonal FL TDP-43 
antibody immunolabeled plaques (arrows, C), apparent NFTs (arrows) and dystrophic neurites (arrowheads, D).   
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